Asset / Drug

masitinib

Drug and asset intelligence for masitinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Biogen →

Recent signals(1)

ClinicalJune 17, 2026

Analysis Reveals Key Trends in ALS Immunotherapeutics Research and Collaboration Gaps

The bibliometric analysis highlights a significant increase in ALS immunotherapeutics research, with a shift towards advanced immunomodulatory strategies and regulatory T cell modulation.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Biogen — masitinib

Monitor developments in regulatory T cell modulation and microglial-targeted approaches, as well as shifts in collaboration patterns among research groups.

June 17, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Amyotrophic Lateral Sclerosis →

Neurology →

Neurology · Amyotrophic Lateral Sclerosis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.